PI3KÎ³ is a molecular switch that controls immune supp

Nature

539, 437-442

DOI: 10.1038/nature19834

Citation Report

#	Article	IF	Citations
1	Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 21-29.	2.0	5
2	Overcoming resistance to checkpoint blockade therapy by targeting PI3KÎ³ in myeloid cells. Nature, 2016, 539, 443-447.	13.7	661
3	Inhibiting macrophage PI3KÎ³ to enhance immunotherapy. Cell Research, 2016, 26, 1267-1268.	5.7	21
4	Small GTPase Rab8a-recruited Phosphatidylinositol 3-Kinase Î³ Regulates Signaling and Cytokine Outputs from Endosomal Toll-like Receptors. Journal of Biological Chemistry, 2017, 292, 4411-4422.	1.6	57
5	Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology. Journal of Leukocyte Biology, 2017, 102, 325-334.	1.5	38
6	PTEN/PI3k/AKT Regulates Macrophage Polarization in Emphysematous mice. Scandinavian Journal of Immunology, 2017, 85, 395-405.	1.3	74
7	The crosstalk between long non-coding RNAs and PI3K in cancer. Medical Oncology, 2017, 34, 39.	1.2	20
8	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017, 168, 707-723.	13.5	3,483
9	New â€œprogrammersâ€•in tissue macrophage activation. Pflugers Archiv European Journal of Physiology, 2017, 469, 375-383.	1.3	7
10	Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Advanced Drug Delivery Reviews, 2017, 114, 206-221.	6.6	528
11	Design and purification of active truncated phosphoinositide 3-kinase gamma protein constructs for structural studies. Protein Expression and Purification, 2017, 135, 1-7.	0.6	3
12	MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells. Immunity, 2017, 46, 730-742.	6.6	179
13	Attenuating PI3K isoforms in pancreatic cancer: Focus on immune PI3KÎ³. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 351-353.	0.7	5
14	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3KÎ´/Î³. Cancer Research, 2017, 77, 2607-2619.	0.4	165
15	Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Experimental and Molecular Medicine, 2017, 49, e311-e311.	3.2	36
16	Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nature Reviews Cancer, 2017, 17, 286-301.	12.8	742
17	The duality of macrophage function in chronic lymphocytic leukaemia. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 176-182.	3.3	10
18	The Promise of Targeting Macrophages in Cancer Therapy. Clinical Cancer Research, 2017, 23, 3241-3250.	3.2	252

#	Article	IF	Citations
19	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs and Aging, 2017, 34, 331-357.	1.3	7
20	Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature, 2017, 543, 728-732.	13.7	403
21	Switching off immune suppression. Nature Reviews Drug Discovery, 2017, 16, 16-17.	21.5	1
22	Switching off immune suppression. Nature Reviews Cancer, 2017, 17, 1-1.	12.8	7
23	Targeting cancerâ€related inflammation in the era of immunotherapy. Immunology and Cell Biology, 2017, 95, 325-332.	1.0	128
25	PI3KÎ³ Activates Integrin Î±4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression. Cancer Immunology Research, 2017, 5, 957-968.	1.6	64
26	PI3KÎ´-selective and PI3KÎ±/Î´-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opinion on Investigational Drugs, 2017, 26, 1267-1279.	1.9	65
27	Combined CDK4/6 and PI3KÎ± Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 6340-6352.	0.4	163
28	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017, 171, 934-949.e16.	13.5	1,515
29	Lack of myeloid Fatp1 increases atherosclerotic lesion size in Ldlr â^'/â^' mice. Atherosclerosis, 2017, 266, 182-189.	0.4	14
30	Regulation of T cell alloimmunity by PI3KÎ³ and PI3KÎ´. Nature Communications, 2017, 8, 951.	5.8	28
32	PI3KÎ³ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity. Science Signaling, 2017, 10, .	1.6	29
33	The adaptor molecule RIAM integrates signaling events critical for integrin-mediated control of immune function and cancer progression. Science Signaling, 2017, 10, .	1.6	39
34	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	2.1	62
35	M1 Means Kill; M2 Means Heal. Journal of Immunology, 2017, 199, 2191-2193.	0.4	214
36	Targeting CXCR4-dependent immunosuppressive Ly6C ^{low} monocytes improves antiangiogenic therapy in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10455-10460.	3.3	97
37	mTOR signaling in immune cells and its implications for cancer immunotherapy. Cancer Letters, 2017, 408, 182-189.	3.2	35
38	The PI3K Pathway in Human Disease. Cell, 2017, 170, 605-635.	13.5	1,702

#	Article	IF	Citations
39	Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. Future Oncology, 2017, 13, 1649-1663.	1.1	10
40	Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. Haematologica, 2017, 102, 1469-1476.	1.7	52
41	Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity. Immunity, 2017, 47, 1169-1181.e7.	6.6	45
42	Microenvironmental regulation of tumour angiogenesis. Nature Reviews Cancer, 2017, 17, 457-474.	12.8	1,299
43	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. Cytokine and Growth Factor Reviews, 2017, 36, 17-24.	3.2	23
44	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. Cytokine and Growth Factor Reviews, 2017, 36, 5-15.	3.2	48
45	Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies. Clinical Cancer Research, 2017, 23, 876-884.	3.2	95
46	Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer. Advances in Experimental Medicine and Biology, 2017, 1026, 331-370.	0.8	16
47	Angiogenesis in metabolic-vascular disease. Thrombosis and Haemostasis, 2017, 117, 1289-1295.	1.8	17
48	Novel GM-CSF signals via IFN-Î³R/IRF-1 and AKT/mTOR license monocytes for suppressor function. Blood Advances, 2017, 1, 947-960.	2.5	78
49	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. Gastrointestinal Cancer: Targets and Therapy, 2017, Volume 7, 1-11.	5.5	49
50	Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment. Cancers, 2017, 9, 24.	1.7	31
51	Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Frontiers in Immunology, 2017, 8, 828.	2.2	295
52	Iron Handling in Tumor-Associated Macrophagesâ€"Is There a New Role for Lipocalin-2?. Frontiers in Immunology, 2017, 8, 1171.	2.2	40
53	Toll-Like Receptor Ligands and Interferon-Î³ Synergize for Induction of Antitumor M1 Macrophages. Frontiers in Immunology, 2017, 8, 1383.	2.2	166
54	Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight, 2017, 2, .	2.3	203
55	Mycobacterium tuberculosis subverts negative regulatory pathways in human macrophages to drive immunopathology. PLoS Pathogens, 2017, 13, e1006367.	2.1	44
56	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget, 2017, 8, 110693-110707.	0.8	115

#	Article	IF	Citations
57	Antiangiogenic therapy and immune checkpoint blockade go hand in hand. Annals of Translational Medicine, 2017, 5, 497-497.	0.7	21
58	Hodgkin lymphoma and PD-1 blockade: an unfinished story. Annals of Lymphoma, 0, 1, 1-1.	4.5	4
59	Umbralisib, a novel PI3KÎ´ and casein kinase-1Îµ inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncology, The, 2018, 19, 486-496.	5.1	178
60	Dual PI3K blockade: PTCLâ€™s Achilles heel?. Blood, 2018, 131, 839-840.	0.6	3
61	The dark side of tumor-associated endothelial cells. Seminars in Immunology, 2018, 35, 35-47.	2.7	82
62	Cancer as a tissue: The significance of cancerâ€stromal interactions in the development, morphogenesis and progression of human upper digestive tract cancer. Pathology International, 2018, 68, 334-352.	0.6	28
63	Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550.	15.2	3,421
64	Canonical PI3KÎ³ signaling in myeloid cells restricts Trypanosoma cruzi infection and dampens chagasic myocarditis. Nature Communications, 2018, 9, 1513.	5.8	19
65	The mesenchymal and myeloid regulation of immunity: Power is nothing without control. Seminars in Immunology, 2018, 35, 1-2.	2.7	1
66	Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends in Molecular Medicine, 2018, 24, 472-489.	3.5	219
67	Therapeutic prospects of targeting myeloidâ€derived suppressor cells and immune checkpoints in cancer. Immunology and Cell Biology, 2018, 96, 888-897.	1.0	43
68	Mouse Models for Studying Oral Cancer: Impact in the Era of Cancer Immunotherapy. Journal of Dental Research, 2018, 97, 683-690.	2.5	15
69	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. Journal of Experimental Medicine, 2018, 215, 859-876.	4.2	150
70	p81. , 2018, , 3766-3766.		0
71	PAR-2. , 2018, , 3785-3785.		0
72	PCS Phosphatase. , 2018, , 3803-3803.		0
73	PIPBP. , 2018, , 4023-4023.		0
74	POSTN. , 2018, , 4111-4111.		0

#	Article	IF	Citations
75	Protein I. , 2018, , 4216-4216.		0
76	PU.1. , 2018, , 4323-4323.		0
77	PVALB (Parvalbumin). , 2018, , 4323-4323.		0
78	PTPe (RPTPe and Cyt-PTPe). , 2018, , 4287-4294.		0
79	Angiogenesis and evading immune destruction are the main related transcriptomic characteristics to the invasive process of oral tongue cancer. Scientific Reports, 2018, 8, 2007.	1.6	13
80	Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nature Reviews Cancer, 2018, 18, 148-167.	12.8	299
81	Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation, 2018, 138, 696-711.	1.6	145
82	Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. Journal of Experimental Medicine, 2018, 215, 877-893.	4.2	111
83	Activity of the PI3K-Î´,Î³ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood, 2018, 131, 888-898.	0.6	224
84	Pyridine Functionalized N-Heterocyclic Silane Complexes of Iridium and Rhodiumâ€“An Unexpected Change in Coordination. Organometallics, 2018, 37, 136-144.	1.1	2
85	Discovering new PI3KÎ± inhibitors with a strategy of combining ligand-based and structure-based virtual screening. Journal of Computer-Aided Molecular Design, 2018, 32, 347-361.	1.3	20
86	MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase Î³ pathway. Rheumatology, 2018, 57, 718-726.	0.9	30
87	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Journal of Hematology and Oncology, 2018, 11, 31.	6.9	256
88	Kinase inhibitors: the road ahead. Nature Reviews Drug Discovery, 2018, 17, 353-377.	21.5	679
89	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity, 2018, 48, 417-433.	6.6	416
90	Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1765-1767.	1.2	49
91	PKB/Akt-dependent regulation of inflammation in cancer. Seminars in Cancer Biology, 2018, 48, 62-69.	4.3	87
92	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Seminars in Cancer Biology, 2018, 48, 91-103.	4.3	257

#	Article	IF	Citations
93	Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy. , 2018, 181, 76-84.		49
94	Metabolism and <scp>TAM</scp> functionsâ€"it takes two to tango. FEBS Journal, 2018, 285, 700-716.	2.2	73
95	Small Molecules Drive Big Improvements in Immunoâ€Oncology Therapies. Angewandte Chemie - International Edition, 2018, 57, 4412-4428.	7.2	116
96	Kleine MolekÃ¼le, ganz groÃŸ: niedermolekulare immunonkologische Kombinationstherapien. Angewandte Chemie, 2018, 130, 4499-4516.	1.6	1
97	A drug development perspective on targeting tumorâ€associated myeloid cells. FEBS Journal, 2018, 285, 763-776.	2.2	31
98	Beyond the Mâ€<scp>CSF</scp> receptor â€" novel therapeutic targets in tumorâ€associated macrophages. FEBS Journal, 2018, 285, 777-787.	2.2	26
99	PI3KÎ³ ablation does not promote diabetes in db/db mice, but improves insulin sensitivity and reduces pancreatic Î²â€cell apoptosis. FASEB Journal, 2018, 32, 319-329.	0.2	11
100	Differential ability of proinflammatory and anti-inflammatory macrophages to perform macropinocytosis. Molecular Biology of the Cell, 2018, 29, 53-65.	0.9	40
101	A Metal-Free Route to Heterocyclic Trifluoromethyl- and Fluoroalkylselenolated Molecules. Organic Letters, 2018, 20, 56-59.	2.4	54
102	Duvelisib, a novel oral dual inhibitor of PI3K-Î´,Î³, is clinically active in advanced hematologic malignancies. Blood, 2018, 131, 877-887.	0.6	199
103	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. Annual Review of Medicine, 2018, 69, 333-347.	5.0	38
104	Kinase inhibitors in clinical practice: An expanding world. Journal of Allergy and Clinical Immunology, 2018, 141, 522-524.	1.5	4
105	PI3K: A master regulator of brain metastasisâ€promoting macrophages/microglia. Glia, 2018, 66, 2438-2455.	2.5	59
106	The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. PeerJ, 2018, 6, e5092.	0.9	36
107	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 157-172.	0.7	40
108	Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Frontiers in Immunology, 2018, 9, 2720.	2.2	33
109	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). , 2018, 6, 114.		41
110	PI3KÎ±/Î´ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity. , 2018, 6, 158.		62

#	Article	IF	Citations
111	A Novel Systems Pharmacology Method to Investigate Molecular Mechanisms of Scutellaria barbata D. Don for Non-small Cell Lung Cancer. Frontiers in Pharmacology, 2018, 9, 1473.	1.6	25
112	The Sweet Surrender: How Myeloid Cell Metabolic Plasticity Shapes the Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2018, 6, 168.	1.8	30
113	PI3â€kinase pathway biomarkers in oral cancer and tumor immune cells. Head and Neck, 2018, 41, 615-622.	0.9	4
114	Integrin CD11b activation drives anti-tumor innate immunity. Nature Communications, 2018, 9, 5379.	5.8	198
115	DUO delivers for duvelisib. Blood, 2018, 132, 2422-2424.	0.6	3
116	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood, 2018, 132, 2446-2455.	0.6	261
117	Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. Frontiers in Immunology, 2018, 9, 1977.	2.2	123
118	Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy. Frontiers in Immunology, 2018, 9, 2250.	2.2	35
119	Targeting macrophages: therapeutic approaches in cancer. Nature Reviews Drug Discovery, 2018, 17, 887-904.	21.5	1,246
120	Exploring optimal sequencing of radiation and immunotherapy combinations. Advances in Radiation Oncology, 2018, 3, 494-505.	0.6	26
121	Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease. Molecular Cell, 2018, 71, 653-673.	4.5	174
122	TLR Crosstalk Activates LRP1 to Recruit Rab8a and PI3KÎ³ for Suppression of Inflammatory Responses. Cell Reports, 2018, 24, 3033-3044.	2.9	67
123	Genetic screen in myeloid cells identifies TNF-Î± autocrine secretion as a factor increasing MDSC suppressive activity via Nos2 up-regulation. Scientific Reports, 2018, 8, 13399.	1.6	19
124	Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Design, Development and Therapy, 2018, Volume 12, 2577-2590.	2.0	49
125	Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. PLoS ONE, 2018, 13, e0193849.	1.1	14
126	Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-Î³ Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 5435-5441.	2.9	35
127	Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization. Cancer Research, 2018, 78, 4929-4942.	0.4	115
128	Macrophage targeting: opening new possibilities for cancer immunotherapy. Immunology, 2018, 155, 285-293.	2.0	123

#	Article	IF	Citations
129	Presymptomatic change in microRNAs modulates Tau pathology. Scientific Reports, 2018, 8, 9251.	1.6	7
130	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
131	Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Frontiers in Physiology, 2018, 9, 335.	1.3	66
132	Galectin-1 Restores Immune Tolerance to Liver Transplantation Through Activation of Hepatic Stellate Cells. Cellular Physiology and Biochemistry, 2018, 48, 863-879.	1.1	16
133	Immuno-Oncology: Emerging Targets and Combination Therapies. Frontiers in Oncology, 2018, 8, 315.	1.3	244
134	Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. Frontiers in Immunology, 2018, 9, 527.	2.2	297
135	Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases. Frontiers in Immunology, 2018, 9, 575.	2.2	65
136	Targeting Macrophages in Cancer: From Bench to Bedside. Frontiers in Oncology, 2018, 8, 49.	1.3	385
137	Buparlisib is a brain penetrable pan-PI3K inhibitor. Scientific Reports, 2018, 8, 10784.	1.6	52
138	Absence of host NF-Î²B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunology, Immunotherapy, 2018, 67, 1491-1503.	2.0	26
139	Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors. Frontiers in Cell and Developmental Biology, 2018, 6, 38.	1.8	171
140	mTORC1 impedes osteoclast differentiation via calcineurin and NFATc1. Communications Biology, 2018, 1, 29.	2.0	53
141	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Frontiers in Immunology, 2018, 9, 1739.	2.2	174
142	Unveiling the Mechanism of Surface Hydrophilicityâ€Modulated Macrophage Polarization. Advanced Healthcare Materials, 2018, 7, e1800675.	3.9	120
143	Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). Cancers of the Head & Neck, 2018, 3, 3.	6.2	58
144	Instructing macrophages to fight cancer. Nature Biomedical Engineering, 2018, 2, 559-561.	11.6	11
145	The homeobox protein VentX reverts immune suppression in the tumor microenvironment. Nature Communications, 2018, 9, 2175.	5.8	28
146	Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3KÎ³ to Promote Pancreatic Cancer Metastasis. Cancer Research, 2018, 78, 4586-4598.	0.4	481

#	Article	IF	Citations
147	Pharmacological inactivation of the PI3K p110Î´ prevents breast tumour progression by targeting cancer cells and macrophages. Cell Death and Disease, 2018, 9, 678.	2.7	37
148	The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Seminars in Cancer Biology, 2018, 52, 107-116.	4.3	57
149	Macrophages. International Review of Cell and Molecular Biology, 2019, 342, 73-93.	1.6	135
150	Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors. Frontiers in Immunology, 2019, 10, 1715.	2.2	38
151	Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression. Cancer Research, 2019, 79, 5048-5059.	0.4	19
152	MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling. Frontiers in Immunology, 2019, 10, 2020.	2.2	11
153	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. Cell Reports, 2019, 28, 2156-2168.e5.	2.9	129
154	Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Frontiers in Immunology, 2019, 10, 1611.	2.2	96
155	Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. Expert Opinion on Investigational Drugs, 2019, 28, 799-809.	1.9	14
156	The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer. Frontiers in Immunology, 2019, 10, 1563.	2.2	77
157	Specific inhibition of PI3KÎ´/Î³ enhances the efficacy of anti-PD1 against osteosarcoma cancer. Journal of Bone Oncology, 2019, 16, 100206.	1.0	18
158	Discovery of a novel phosphoinositide 3-kinase gamma (PI3KÎ³) inhibitor against hematologic malignancies and theoretical studies on its PI3KÎ³-specific binding mechanisms. RSC Advances, 2019, 9, 20207-20215.	1.7	15
159	Macrophage-Mediated Subversion of Anti-Tumour Immunity. Cells, 2019, 8, 747.	1.8	68
160	Inhibiting PI3 kinase-Î³ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors. Journal of Controlled Release, 2019, 309, 173-180.	4.8	35
161	p110Î³ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14724-14733.	3.3	22
162	Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptideâ€Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA. Advanced Materials, 2019, 31, e1902952.	11.1	73
163	Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 2019, 30, 36-50.	7.2	933
164	Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells. , 2019, 7, 261.		82

#	Article	IF	Citations
165	Common gamma chain cytokines and CD8 T cells in cancer. Seminars in Immunology, 2019, 42, 101307.	2.7	25
166	Signal Integration and Transcriptional Regulation of the Inflammatory Response Mediated by the GM-/M-CSF Signaling Axis in Human Monocytes. Cell Reports, 2019, 29, 860-872.e5.	2.9	29
167	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. Journal of Hematology and Oncology, 2019, 12, 111.	6.9	93
168	Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing. Frontiers in Oncology, 2019, 9, 1115.	1.3	21
169	The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. Biomolecules, 2019, 9, 713.	1.8	17
170	Small molecules as theranostic agents in cancer immunology. Theranostics, 2019, 9, 7849-7871.	4.6	42
171	(3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3KÎ´/Î³. Immunopharmacology and Immunotoxicology, 2019, 41, 599-606.	1.1	1
172	The Endless Saga of Monocyte Diversity. Frontiers in Immunology, 2019, 10, 1786.	2.2	67
173	Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. Future Oncology, 2019, 15, 2227-2239.	1.1	13
174	Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nature Cell Biology, 2019, 21, 1113-1126.	4.6	202
175	TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Antiâ€“PD-1 Therapy in Melanoma. Cancer Immunology Research, 2019, 7, 1672-1686.	1.6	85
176	The Role of PTEN in Innate and Adaptive Immunity. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a036996.	2.9	24
177	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Molecular Cancer, 2019, 18, 139.	7.9	156
178	Discovery of potent ureido tetrahydrocarbazole derivatives for cancer treatments through targeting tumor-associated macrophages. European Journal of Medicinal Chemistry, 2019, 183, 111741.	2.6	10
179	Tumors vs. Chronic Wounds: An Immune Cell's Perspective. Frontiers in Immunology, 2019, 10, 2178.	2.2	52
180	Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression. International Journal of Molecular Sciences, 2019, 20, 4719.	1.8	48
181	Human PI3KÎ³ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nature Communications, 2019, 10, 4364.	5.8	51
182	Current targeted therapies in lymphomas. American Journal of Health-System Pharmacy, 2019, 76, 1825-1834.	0.5	19

#	Article	IF	Citations
183	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. Cancer Microenvironment, 2019, 12, 119-132.	3.1	46
184	Function, Regulation and Biological Roles of PI3KÎ³ Variants. Biomolecules, 2019, 9, 427.	1.8	28
185	A Blazing Landscape: Neuroinflammation Shapes Brain Metastasis. Cancer Research, 2019, 79, 423-436.	0.4	60
186	Antiâ€“PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. Cancer Research, 2019, 79, 1493-1506.	0.4	118
187	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repairâ€“Deficient Colorectal Cancer. Cancer Immunology Research, 2019, 7, 1230-1236.	1.6	59
188	Cellular Senescence and the Immune System in Cancer. Gerontology, 2019, 65, 505-512.	1.4	66
189	Multifunctional Nanoregulator Reshapes Immune Microenvironment and Enhances Immune Memory for Tumor Immunotherapy. Advanced Science, 2019, 6, 1900037.	5.6	94
190	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. Cardiac Failure Review, 2019, 5, 112-118.	1.2	39
191	Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer. Translational Oncology, 2019, 12, 1038-1044.	1.7	39
192	Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-Î²1/smad2/3 axis in pancreatic cancer. Cancer Letters, 2019, 459, 204-215.	3.2	48
193	Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and SÃ©zary Syndrome. Frontiers in Medicine, 2019, 6, 116.	1.2	28
194	Cancer and Microenvironment Plasticity: Double-Edged Swords in Metastasis. Trends in Pharmacological Sciences, 2019, 40, 419-429.	4.0	43
195	Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPSâ€“) vs. Alternatively Activated Macrophages. Frontiers in Immunology, 2019, 10, 1084.	2.2	1,202
196	PI3K isoforms in cell signalling andÂvesicle trafficking. Nature Reviews Molecular Cell Biology, 2019, 20, 515-534.	16.1	316
197	Phosphoinositide 3â€kinaseÂÎ³is a regulatory Tâ€cell target in cancer immunotherapy. Immunology, 2019, 157, 210-218.	2.0	30
198	PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. Cancer Letters, 2019, 457, 74-85.	3.2	15
199	Re-education of macrophages as a therapeutic strategy in cancer. Immunotherapy, 2019, 11, 677-689.	1.0	124
200	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459

#	Article	IF	Citations
201	SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. Molecular Cancer Therapeutics, 2019, 18, 1036-1044.	1.9	35
202	PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(<scp>l</scp>â€Glutamic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	5.6	46
203	What makes a planet habitable?. Science, 2019, 364, 434-435.	6.0	18
204	Modulating inflammation for cancer therapy. Journal of Experimental Medicine, 2019, 216, 1234-1243.	4.2	108
205	Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. Cancers, 2019, 11, 298.	1.7	10
206	HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood. Journal of Virology, 2019, 93, .	1.5	24
207	Structural Determinants of Isoform Selectivity in PI3K Inhibitors. Biomolecules, 2019, 9, 82.	1.8	55
208	Tumor-specific macrophage targeting through recognition of retinoid X receptor beta. Journal of Controlled Release, 2019, 301, 42-53.	4.8	36
209	Role of miRNAs in Melanoma Metastasis. Cancers, 2019, 11, 326.	1.7	64
210	Targeting Tumor-Associated Macrophages in Cancer. Trends in Immunology, 2019, 40, 310-327.	2.9	660
211	Tailoring Nanomaterials for Targeting Tumorâ€Associated Macrophages. Advanced Materials, 2019, 31, e1808303.	11.1	223
212	Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nature Neuroscience, 2019, 22, 729-740.	7.1	327
213	Mouse Models as a Tool for Understanding Progression in Braf^{V600E}-Driven Thyroid Cancers. Endocrinology and Metabolism, 2019, 34, 11.	1.3	14
214	Rab8a localisation and activation by Toll-like receptors on macrophage macropinosomes. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180151.	1.8	24
215	Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression. Cell Metabolism, 2019, 29, 1376-1389.e4.	7.2	261
216	Gab2 and Gab3 Redundantly Suppress Colitis by Modulating Macrophage and CD8+ T-Cell Activation. Frontiers in Immunology, 2019, 10, 486.	2.2	11
217	Targeting PI3K-Gamma in Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2019, 37, 932-934.	0.8	7
218	Microbiome Dependent Regulation of Tregs and Th17 Cells in Mucosa. Frontiers in Immunology, 2019, 10, 426.	2.2	163

#	Article	IF	Citations
219	Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. Journal of Oncology, 2019, 2019, 1-18.	0.6	76
220	Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors. Clinical Cancer Research, 2019, 25, 3289-3303.	3.2	73
221	Targeting PI3K in cancer: mechanisms and advances in clinical trials. Molecular Cancer, 2019, 18, 26.	7.9	940
222	Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. Annual Review of Physiology, 2019, 81, 535-560.	5.6	44
223	Phosphatidylinositol 3 Kinase Î´ Inhibitors. Cancer Journal (Sudbury, Mass), 2019, 25, 394-400.	1.0	22
224	Immune and Smooth Muscle Cells Interactions in Atherosclerosis: How to Target a Breaking Bad Dialogue?. Frontiers in Pharmacology, 2019, 10, 1276.	1.6	31
225	Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. , 2019, 7, 328.		65
226	Unmasking the Many Faces of Tumor-Associated Neutrophils and Macrophages: Considerations for Targeting Innate Immune Cells in Cancer. Trends in Cancer, 2019, 5, 789-798.	3.8	56
227	ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitorsâ€"A STING in the Tale of ENPP1. Molecules, 2019, 24, 4192.	1.7	66
228	Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Molecular Cancer, 2019, 18, 177.	7.9	235
229	Recent discovery of phosphoinositide 3-kinase Î³ inhibitors for the treatment of immune diseases and cancers. Future Medicinal Chemistry, 2019, 11, 2151-2169.	1.1	13
230	Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets. Cancers, 2019, 11, 1972.	1.7	8
231	PI3KÎ´ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1427-1438.	3.3	51
232	The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves. Journal of Immunology, 2019, 202, 11-19.	0.4	92
233	Global Proteomic and Methylome Analysis in Human Induced Pluripotent Stem Cells Reveals Overexpression of a Human TLR3 Affecting Proper Innate Immune Response Signaling. Stem Cells, 2019, 37, 476-488.	1.4	7
234	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 199-224.	3.3	53
235	Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. British Journal of Cancer, 2019, 120, 16-25.	2.9	504
236	Cationic polysaccharide spermine-pullulan drives tumor associated macrophage towards M1 phenotype to inhibit tumor progression. International Journal of Biological Macromolecules, 2019, 123, 1012-1019.	3.6	27

#	Article	IF	Citations
237	Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly. Cancer Immunology, Immunotherapy, 2019, 68, 269-282.	2.0	19
238	Function, clinical application, and strategies of Pre-mRNA splicing in cancer. Cell Death and Differentiation, 2019, 26, 1181-1194.	5.0	64
239	Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3KÎ´/Î³ Inhibitor RP6530. Clinical Cancer Research, 2019, 25, 1098-1112.	3.2	69
240	Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Letters, 2019, 442, 91-103.	3.2	41
241	Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages. Cancer Immunology Research, 2019, 7, 193-207.	1.6	64
242	Targeting the immunity protein kinases for immuno-oncology. European Journal of Medicinal Chemistry, 2019, 163, 413-427.	2.6	12
243	Mechanisms of Resistance to Immune Checkpoint Blockade. American Journal of Clinical Dermatology, 2019, 20, 41-54.	3.3	83
244	Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia. Molecular Immunology, 2019, 110, 77-87.	1.0	24
245	Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance. Molecular Immunology, 2019, 110, 3-12.	1.0	45
246	Tumour-intrinsic resistance to immune checkpoint blockade. Nature Reviews Immunology, 2020, 20, 25-39.	10.6	856
247	Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease. Advances in Biological Regulation, 2020, 75, 100657.	1.4	62
248	The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer. Seminars in Cancer Biology, 2020, 60, 57-71.	4.3	90
249	Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cellular and Molecular Immunology, 2020, 17, 1-12.	4.8	273
250	Knockdown of SGK1 alleviates the ILâ€1Î²â€induced chondrocyte anabolic and catabolic imbalance by activating FoxO1â€mediated autophagy in human chondrocytes. FEBS Journal, 2020, 287, 94-107.	2.2	30
251	PI3K-p110Î´ contributes to antibody responses by macrophages in chronic lymphocytic leukemia. Leukemia, 2020, 34, 451-461.	3.3	8
252	Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in nonâ€small cell lung cancer. Journal of Pathology, 2020, 250, 19-29.	2.1	92
253	Polarization of tumor-associated macrophage phenotype via porous hollow iron nanoparticles for tumor immunotherapy in vivo. Nanoscale, 2020, 12, 130-144.	2.8	83
254	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. Seminars in Cancer Biology, 2020, 65, 51-64.	4.3	63

#	Article	IF	Citations
255	Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. Advanced Drug Delivery Reviews, 2020, 165-166, 15-40.	6.6	146
256	Brain immunology and immunotherapy in brain tumours. Nature Reviews Cancer, 2020, 20, 12-25.	12.8	389
257	Theoretical investigation of a cationâ€controllable molecular shuttle of tetracationic cyclophane. Journal of Physical Organic Chemistry, 2020, 33, e4036.	0.9	0
258	Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses. Cells, 2020, 9, 46.	1.8	196
259	27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression. Cancer Letters, 2020, 493, 266-283.	3.2	51
260	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. Chinese Medical Journal, 2020, 133, 2444-2455.	0.9	7
261	Lipid accumulation in macrophages confers protumorigenic polarization and immunity in gastric cancer. Cancer Science, 2020, 111, 4000-4011.	1.7	52
262	Breast cancer cell debris diminishes therapeutic efficacy through heme oxygenase-1-mediated inactivation of M1-like tumor-associated macrophages. Neoplasia, 2020, 22, 606-616.	2.3	15
263	Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. International Immunopharmacology, 2020, 88, 106939.	1.7	153
264	Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy. Pharmacological Research, 2020, 161, 105111.	3.1	68
265	In vivo microscopy reveals macrophage polarization locally promotes coherent microtubule dynamics in migrating cancer cells. Nature Communications, 2020, 11, 3521.	5.8	17
266	PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer. Drug Discovery Today, 2020, 25, 1762-1771.	3.2	25
267	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1820-1834.	1.8	51
268	Modified Jian-pi-yang-zheng decoction inhibits gastric cancer progression via the macrophage immune checkpoint PI3Kî³. Biomedicine and Pharmacotherapy, 2020, 129, 110440.	2.5	15
269	Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer. Cancers, 2020, 12, 3377.	1.7	35
270	Tumor necrosis factor Î± inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer. Cell Death and Disease, 2020, 11, 993.	2.7	31
271	Tumor-macrophage crosstalk: how to listen. Integrative Biology (United Kingdom), 2020, 12, 291-302.	0.6	5
272	Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPÎ± Axis. Frontiers in Immunology, 2020, 11, 593219.	2.2	38

#	Article	IF	Citations
273	Metabolic Cancer-Macrophage Crosstalk in the Tumor Microenvironment. Biology, 2020, 9, 380.	1.3	16
274	Overcoming Immune Evasion in Melanoma. International Journal of Molecular Sciences, 2020, 21, 8984.	1.8	88
275	Immunotherapy Targeting Tumor-Associated Macrophages. Frontiers in Medicine, 2020, 7, 583708.	1.2	15
276	Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. Frontiers in Immunology, 2020, 11, 1590.	2.2	50
277	Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. International Journal of Molecular Sciences, 2020, 21, 5207.	1.8	119
278	Artesunate reverses LPS tolerance by promoting ULK1-mediated autophagy through interference with the CaMKII-IP3R-CaMKKÎ² pathway. International Immunopharmacology, 2020, 87, 106863.	1.7	10
279	Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment. Cancers, 2020, 12, 1960.	1.7	20
280	Tumor-Associated Macrophage Status in Cancer Treatment. Cancers, 2020, 12, 1987.	1.7	101
281	Stromal regulation of tumor-associated lymphatics. Advanced Drug Delivery Reviews, 2020, 161-162, 75-89.	6.6	6
282	FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy. Nature Communications, 2020, 11, 4064.	5.8	76
283	Tumor-Associated Neutrophils and Macrophagesâ€"Heterogenous but Not Chaotic. Frontiers in Immunology, 2020, 11, 553967.	2.2	53
284	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biology, 2020, 21, 263.	3.8	15
285	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. Cancers, 2020, 12, 3129.	1.7	29
286	PIK3CG Is a Potential Therapeutic Target in Androgen Receptorâ€"Indifferent Metastatic Prostate Cancer. American Journal of Pathology, 2020, 190, 2194-2202.	1.9	9
287	Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in Immunology, 2020, 11, 1956.	2.2	143
288	Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. BioDrugs, 2020, 34, 611-623.	2.2	38
289	Exploiting Manipulated Small Extracellular Vesicles to Subvert Immunosuppression at the Tumor Microenvironment through Mannose Receptor/CD206 Targeting. International Journal of Molecular Sciences, 2020, 21, 6318.	1.8	17
290	Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment. Frontiers in Immunology, 2020, 11, 1842.	2.2	28

#	Article	IF	Citations
291	Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3KÎ³ Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 2244-2252.	1.3	13
292	Nanomedicine-based tumor photothermal therapy synergized immunotherapy. Biomaterials Science, 2020, 8, 5241-5259.	2.6	109
293	Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets. Annals of Translational Medicine, 2020, 8, 1031-1031.	0.7	5
294	Discovery of Potent and Selective PI3KÎ³ Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 11235-11257.	2.9	28
295	Blocking P2X7-Mediated Macrophage Polarization Overcomes Treatment Resistance in Lung Cancer. Cancer Immunology Research, 2020, 8, 1426-1439.	1.6	35
296	Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity. Acta Pharmacologica Sinica, 2020, 41, 1395-1402.	2.8	32
297	Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections. Advances in Experimental Medicine and Biology, 2020, 1274, 203-222.	0.8	16
298	Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine, 2020, 12, .	5.8	34
299	Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. International Journal of Molecular Sciences, 2020, 21, 5845.	1.8	51
300	Thymosin Î²10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma. Respiratory Research, 2020, 21, 328.	1.4	18
301	A Case for Phosphoinositide 3-Kinaseâ€“Targeted Therapy for Infectious Disease. Journal of Immunology, 2020, 205, 3237-3245.	0.4	6
302	Gβγ is a direct regulator of endogenous p101/p110Î³ and p84/p110Î³ PI3KÎ³ complexes in mouse neutrophils. Science Signaling, 2020, 13, .	1.6	19
303	SHC014748M, a novel selective inhi-bitor of PI3KÎ´, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. Neoplasia, 2020, 22, 714-724.	2.3	9
304	Small moleculesâ€”Giant leaps for immuno-oncology. Progress in Medicinal Chemistry, 2020, 59, 1-62.	4.1	2
305	Solute Carrier Family 37 Member 2 (SLC37A2) Negatively Regulates Murine Macrophage Inflammation by Controlling Glycolysis. IScience, 2020, 23, 101125.	1.9	12
306	Effective combinatorial immunotherapy for penile squamous cell carcinoma. Nature Communications, 2020, 11, 2124.	5.8	45
307	Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Cancer Letters, 2020, 485, 1-13.	3.2	10
308	Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8⁺ T cells. European Journal of Immunology, 2020, 50, 1386-1399.	1.6	38

#	Article	IF	Citations
309	Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer . Cancer Management and Research, 2020, Volume 12, 2641-2651.	0.9	8
310	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. Scientific Reports, 2020, 10, 8867.	1.6	13
311	Rel-ating myeloid cells to cancer therapy. Nature Cancer, 2020, 1, 480-481.	5.7	2
312	Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer and Metastasis Reviews, 2020, 39, 711-720.	2.7	82
313	Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3KÎ³ isoform. Communications Biology, 2020, 3, 267.	2.0	21
314	Blocking immunosuppressive neutrophils deters pY696-EZH2â€“driven brain metastases. Science Translational Medicine, 2020, 12, .	5.8	64
315	IRE1Î± regulates macrophage polarization, PD-L1 expression, and tumor survival. PLoS Biology, 2020, 18, e3000687.	2.6	42
316	Rational Cancer Treatment Combinations: An Urgent Clinical Need. Molecular Cell, 2020, 78, 1002-1018.	4.5	95
317	Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 4441.	1.8	20
318	Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. OMICS A Journal of Integrative Biology, 2020, 24, 314-339.	1.0	35
319	Restoration of miR-340 controls pancreatic cancer cellCD47expression to promote macrophage phagocytosis and enhance antitumor immunity. , 2020, 8, e000253.		33
320	Differently Charged Super-Paramagnetic Iron Oxide Nanoparticles Preferentially Induced M1-Like Phenotype of Macrophages. Frontiers in Bioengineering and Biotechnology, 2020, 8, 537.	2.0	41
321	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	0.8	7
322	The spectrum of macrophage activation by immunometabolism. International Immunology, 2020, 32, 467-473.	1.8	26
323	Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression. Cell, 2020, 180, 1098-1114.e16.	13.5	140
324	Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Expert Opinion on Pharmacotherapy, 2020, 21, 917-929.	0.9	23
325	The on-off action of Forkhead protein O3a in endotoxin tolerance of Kupffer cells depends on the PI3K/AKT pathway. International Immunopharmacology, 2020, 82, 106342.	1.7	3
326	Pharmacological targets of metabolism in disease: Opportunities from macrophages. , 2020, 210, 107521.		45

#	Article	IF	Citations
327	Signaling networks in immunometabolism. Cell Research, 2020, 30, 328-342.	5.7	120
328	Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Review of Anticancer Therapy, 2020, 20, 289-304.	1.1	13
329	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.2	12
330	New tools to prevent cancer growth and spread: a â€˜Cleverâ€™ approach. British Journal of Cancer, 2020, 123, 501-509.	2.9	34
331	How to use macrophages to realise the treatment of tumour. Journal of Drug Targeting, 2020, 28, 1034-1045.	2.1	8
332	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. Journal of Clinical Medicine, 2020, 9, 1973.	1.0	10
333	The dual PI3KÎ´/CK1Îµ inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Advances, 2020, 4, 3072-3084.	2.5	52
334	Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 4414.	1.8	87
335	Counter Regulation of Spic by NF-ÎºB and STAT Signaling Controls Inflammation and Iron Metabolism in Macrophages. Cell Reports, 2020, 31, 107825.	2.9	28
336	Modeling chemical effects on breast cancer: the importance of the microenvironment in vitro. Integrative Biology (United Kingdom), 2020, 12, 21-33.	0.6	9
337	Biology and therapeutic targeting of tumourâ€associated macrophages. Journal of Pathology, 2020, 250, 573-592.	2.1	56
338	TAK1 signaling activity links the mast cell cytokine response and degranulation in allergic inflammation. Journal of Leukocyte Biology, 2020, 107, 649-661.	1.5	12
339	Structurally novel PI3KÎ´/Î³ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation. European Journal of Medicinal Chemistry, 2020, 191, 112143.	2.6	9
340	Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages. Cancer Letters, 2020, 474, 36-52.	3.2	200
341	Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. Seminars in Cancer Biology, 2020, 65, 38-50.	4.3	34
342	PDâ€1/PDâ€L1â€dependent immune response in colorectal cancer. Journal of Cellular Physiology, 2020, 235, 5461-5475.	2.0	86
343	Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Brain Tumor Pathology, 2020, 37, 41-49.	1.1	37
344	Macrophage Sykâ€“PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Sykâ€“PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics, 2020, 19, 755-764.	1.9	24

#	Article	IF	Citations
345	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity, 2020, 52, 36-54.	6.6	127
346	Prioritizing Gene Cascading Paths to Model Colorectal Cancer Through Engineered Organoids. Frontiers in Bioengineering and Biotechnology, 2020, 8, 12.	2.0	7
347	Remodeling tumor immune microenvironment via targeted blockade of PI3K-Î³ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy. Journal of Controlled Release, 2020, 321, 23-35.	4.8	123
348	PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma. Current Treatment Options in Oncology, 2020, 21, 51.	1.3	27
349	Lifting the innate immune barriers to antitumor immunity. , 2020, 8, e000695.		50
350	M2 polarization of tumorâ€associated macrophages is dependent on integrin Î²3 via peroxisome proliferatorâ€activated receptorâ€Î³ upâ€regulation in breast cancer. Immunology, 2020, 160, 345-356.	2.0	32
351	Synthetic Approaches to New Drugs Approved during 2018. Journal of Medicinal Chemistry, 2020, 63, 10652-10704.	2.9	33
352	Targeting tumor-associated macrophages in head and neck squamous cell carcinoma. Oral Oncology, 2020, 106, 104723.	0.8	41
353	Duvelisib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy, 2020, 21, 1299-1309.	0.9	13
354	Low-Dose Decitabine Assists Human Umbilical Cord-Derived Mesenchymal Stem Cells in ProtectingÎ²Cells via the Modulation of the Macrophage Phenotype in Type 2 Diabetic Mice. Stem Cells International, 2020, 2020, 1-17.	1.2	8
355	Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment. Cancer Biology and Medicine, 2020, 17, 32-43.	1.4	51
356	Germline biallelic PIK3CG mutations in a multifaceted immunodeficiency with immune dysregulation. Haematologica, 2020, 105, e488.	1.7	17
357	The unique immune microenvironment of liver metastases: Challenges and opportunities. Seminars in Cancer Biology, 2021, 71, 143-156.	4.3	35
358	Resistance mechanisms to immune checkpointsÂblockade by monoclonal antibody drugs in cancer immunotherapy: FocusÂon myeloma. Journal of Cellular Physiology, 2021, 236, 791-805.	2.0	13
359	A novel selective autophagy receptor, CCDC50, delivers K63Âpolyubiquitination-activated RIG-I/MDA5 for degradation during viral infection. Cell Research, 2021, 31, 62-79.	5.7	55
360	The role of PI3K inhibitors in the treatment of malignant lymphomas. Leukemia and Lymphoma, 2021, 62, 517-527.	0.6	5
361	Cargo-laden erythrocyte ghosts target liver mediated by macrophages. Transfusion and Apheresis Science, 2021, 60, 102930.	0.5	7
362	Targeting tumorâ€associated macrophages: A potential treatment for solid tumors. Journal of Cellular Physiology, 2021, 236, 3445-3465.	2.0	35

#	Article	IF	Citations
363	Tumor microenvironment as a therapeutic target in cancer. , 2021, 221, 107753.		567
364	Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Molecular Medicine, 2021, 13, e12798.	3.3	59
365	Targeting tumor-associated macrophages as an antitumor strategy. Biochemical Pharmacology, 2021, 183, 114354.	2.0	88
366	Varied functions of immune checkpoints during cancer metastasis. Cancer Immunology, Immunotherapy, 2021, 70, 569-588.	2.0	14
367	The role of YY1 in drug resistant cancer: Involvement of the YY1/PTEN/PP2A/H2Ax/Rad51 axis. , 2021, , 225-242.		0
368	The immunomodulatory effects of endocrine therapy in breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 19.	3.5	36
369	Chimeric Antigen Receptor beyond CAR-T Cells. Cancers, 2021, 13, 404.	1.7	29
370	Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors. Frontiers in Immunology, 2020, 11, 604967.	2.2	12
371	Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?. Frontiers in Immunology, 2020, 11, 595818.	2.2	13
372	Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy. Frontiers in Oncology, 2020, 10, 614468.	1.3	38
373	Tumor-associated myeloid cells: diversity and therapeutic targeting. Cellular and Molecular Immunology, 2021, 18, 566-578.	4.8	100
374	Cancer Stemness Meets Immunity: From Mechanism to Therapy. Cell Reports, 2021, 34, 108597.	2.9	128
375	Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications. Journal of Cancer, 2021, 12, 54-64.	1.2	46
376	Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy. Expert Review of Anticancer Therapy, 2021, 21, 481-488.	1.1	5
377	Therapeutic Manipulation of Tumor-associated Macrophages: Facts and Hopes from a Clinical and Translational Perspective. Clinical Cancer Research, 2021, 27, 3291-3297.	3.2	42
378	Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 75.	7.1	323
379	CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model. Journal of Immunology, 2021, 206, 1372-1384.	0.4	13
380	Targeting Innate Immunity in Cancer Therapy. Vaccines, 2021, 9, 138.	2.1	57

#	Article	IF	Citations
381	Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention. Cancers, 2021, 13, 641.	1.7	7
382	The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. Journal of Clinical Medicine, 2021, 10, 566.	1.0	21
383	Myeloid NEMO deficiency promotes tumor immunosuppression partly via MCP1-CCR2 axis. Experimental Cell Research, 2021, 399, 112467.	1.2	1
384	The characteristics of regulatory macrophages and their roles in transplantation. International Immunopharmacology, 2021, 91, 107322.	1.7	16
385	Determinants, mechanisms, and functional outcomes of myeloid cell diversity in cancer. Immunological Reviews, 2021, 300, 220-236.	2.8	5
386	Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. Frontiers in Oncology, 2021, 11, 614332.	1.3	33
388	Inhibition of PI3K Isoform p110Î³ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity. Cancers, 2021, 13, 953.	1.7	11
389	The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies. IUBMB Life, 2021, 73, 618-642.	1.5	19
390	Tumorâ€associated macrophages in immunotherapy. FEBS Journal, 2021, 288, 6174-6186.	2.2	48
391	Establishment and validation of an eight-gene metabolicâ€“related prognostic signature model for lung adenocarcinoma. Aging, 2021, 13, 8688-8705.	1.4	6
392	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15
393	Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3KÎ³ Inhibition. Molecular Cancer Therapeutics, 2021, 20, 1080-1091.	1.9	7
394	Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives. Breast Cancer, 2021, 28, 539-555.	1.3	60
395	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers, 2021, 13, 1300.	1.7	10
396	Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. International Journal of Nanomedicine, 2021, Volume 16, 1631-1661.	3.3	19
397	PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. International Journal of Molecular Sciences, 2021, 22, 3464.	1.8	119
398	The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy. European Journal of Cell Biology, 2021, 100, 151153.	1.6	10
399	Roles of Macrophages in the Development and Treatment of Gut Inflammation. Frontiers in Cell and Developmental Biology, 2021, 9, 625423.	1.8	87

#	Article	IF	Citations
400	Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 2608.	1.8	13
401	Gene silencing delivery systems for the treatment of pancreatic cancer: Where and what to target next?. Journal of Controlled Release, 2021, 331, 246-259.	4.8	18
402	Disease-related mutations in PI3KÎ³ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. ELife, 2021, 10, .	2.8	28
403	Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy. Cells, 2021, 10, 960.	1.8	33
404	Tumor-Associated Macrophagesâ€"Implications for Molecular Oncology and Imaging. Biomedicines, 2021, 9, 374.	1.4	10
405	Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 633685.	2.2	4
406	Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell, 2021, 184, 2033-2052.e21.	13.5	107
407	Research progress in tumor targeted immunotherapy. Expert Opinion on Drug Delivery, 2021, 18, 1067-1090.	2.4	11
408	Major signaling pathways and key mediators of macrophages in acute kidney injury (Review). Molecular Medicine Reports, 2021, 23, .	1.1	14
409	Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery, 2021, 11, 1368-1397.	7.7	130
411	Distinct roles of PI3KÎ´ and PI3KÎ³ in a toluene diisocyanate-induced murine asthma model. Toxicology, 2021, 454, 152747.	2.0	5
412	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology, 2021, 23, 1922-1935.	0.6	33
413	PI3KÎ³ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	33
414	A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications. Translational Lung Cancer Research, 2021, 10, 1889-1916.	1.3	68
415	Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies. Frontiers in Immunology, 2021, 12, 609762.	2.2	23
417	Therapeutic Targeting of the Tumor Microenvironment. Cancer Discovery, 2021, 11, 933-959.	7.7	646
418	The Role of Macrophages in Cancer Development and Therapy. Cancers, 2021, 13, 1946.	1.7	143
419	Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer. Frontiers in Immunology, 2021, 12, 643771.	2.2	80

#	Article	IF	Citations
420	Current Treatment Options in CLL. Cancers, 2021, 13, 2468.	1.7	20
421	Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016â€“2020). Expert Opinion on Therapeutic Patents, 2021, 31, 877-892.	2.4	27
422	Umbralisib, a Dual PI3KÎ´/CK1Îµ Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology, 2021, 39, 1609-1618.	0.8	111
423	Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes. Frontiers in Immunology, 2021, 12, 642285.	2.2	70
424	Radiomic biomarkers of tumor immune biology and immunotherapy response. Clinical and Translational Radiation Oncology, 2021, 28, 97-115.	0.9	22
425	Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCsâ€Targeting Immunotherapy of Colon Cancer. Advanced Science, 2021, 8, e2100712.	5.6	59
426	Prognostic Significance of Tumor-Associated Macrophages in Chondroblastoma and Their Association with Response to Adjuvant Radiotherapy. Journal of Inflammation Research, 2021, Volume 14, 1991-2005.	1.6	6
427	Redefining macrophage and neutrophil biology in the metastatic cascade. Immunity, 2021, 54, 885-902.	6.6	68
428	The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors. Frontiers in Molecular Biosciences, 2021, 8, 648663.	1.6	23
429	Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy. Brain Tumor Pathology, 2021, 38, 149-155.	1.1	7
430	Tumor-associated macrophages: Shifting bad prognosis to improved efficacy in cancer therapies?. International Journal of Immunotherapy and Cancer Research, 2021, , 015-023.	0.4	1
431	Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention. Current Treatment Options in Oncology, 2021, 22, 52.	1.3	1
433	Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment. Acta Pharmaceutica Sinica B, 2021, 11, 1365-1378.	5.7	38
434	The present and future of PI3K inhibitors for cancer therapy. Nature Cancer, 2021, 2, 587-597.	5.7	63
435	Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy. Frontiers in Oncology, 2021, 11, 693146.	1.3	5
436	Î±-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis Effect of Lung Cancer Cells. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-16.	1.9	12
437	Tumor-Associated Macrophages: A Potential Target for Cancer Therapy. Frontiers in Oncology, 2021, 11, 693517.	1.3	46
438	Neural guidance factors as hubs of immunometabolic cross-talk. International Immunology, 2021, 33, 749-754.	1.8	3

#	Article	IF	Citations
439	Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges. Cancers, 2021, 13, 2860.	1.7	39
440	Turning enemies into alliesâ€"reprogramming tumor-associated macrophages for cancer therapy. Med, 2021, 2, 666-681.	2.2	17
441	Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. Nature Communications, 2021, 12, 3530.	5.8	68
442	Redirecting macrophage function to sustain their â€œdefenderâ€•antitumor activity. Cancer Cell, 2021, 39, 734-737.	7.7	13
443	Macrophages in Acute Myeloid Leukaemia: Significant Players in Therapy Resistance and Patient Outcomes. Frontiers in Cell and Developmental Biology, 2021, 9, 692800.	1.8	27
444	Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy. AAPS Journal, 2021, 23, 90.	2.2	19
445	Tumor-derived exosomal microRNA-106b-5p activates EMT-cancer cell and M2-subtype TAM interaction to facilitate CRC metastasis. Molecular Therapy, 2021, 29, 2088-2107.	3.7	89
447	A Review of Phosphocreatine 3 Kinase d Subtype (PI3KÎ´) and Its Inhibitors in Malignancy. Medical Science Monitor, 2021, 27, e932772.	0.5	3
448	Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers, 2021, 13, 3666.	1.7	25
449	Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 707198.	1.8	17
450	Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Molecular Therapy, 2021, 29, 2321-2334.	3.7	48
451	FGF21 alleviates chronic inflammatory injury in the aging process through modulating polarization of macrophages. International Immunopharmacology, 2021, 96, 107634.	1.7	6
452	The Host Cellular Immune Response to Infection by Campylobacter Spp. and Its Role in Disease. Infection and Immunity, 2021, 89, e0011621.	1.0	19
454	The therapeutic implications of immunosuppressive tumor aerobic glycolysis. Cellular and Molecular Immunology, 2022, 19, 46-58.	4.8	39
455	The Importance of Being PI3K in the RAS Signaling Network. Genes, 2021, 12, 1094.	1.0	28
456	Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma. Frontiers in Immunology, 2021, 12, 650105.	2.2	15
457	Loss of fragile site-associated tumor suppressor promotes antitumor immunity via macrophage polarization. Nature Communications, 2021, 12, 4300.	5.8	14
458	Sizeâ€Confined Effects of Nanostructures on Fibronectinâ€Induced Macrophage Inflammation on Titanium Implants. Advanced Healthcare Materials, 2021, 10, e2100994.	3.9	17

#	Article	IF	Citations
459	p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition. , 2021, 9, e002319.		19
460	Circadian regulation of cancer cell and tumor microenvironment crosstalk. Trends in Cell Biology, 2021, 31, 940-950.	3.6	42
461	GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. , 2021, 9, e003005.		22
462	Chemical Oral Cancerogenesis Is Impaired in PI3KÎ³ Knockout and Kinase-Dead Mice. Cancers, 2021, 13, 4211.	1.7	3
463	Structure of the phosphoinositide 3-kinase (PI3K) p110Î³-p101 complex reveals molecular mechanism of GPCR activation. Science Advances, 2021, 7, .	4.7	25
464	HDX-MS-optimized approach to characterize nanobodies as tools for biochemical and structural studies of class IB phosphoinositide 3-kinases. Structure, 2021, 29, 1371-1381.e6.	1.6	10
465	The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2021, 35, 807-826.	0.9	7
466	Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation. American Journal of Physiology - Cell Physiology, 2021, 321, C721-C734.	2.1	14
467	Dual Inhibition of Endoplasmic Reticulum Stress and Oxidation Stress Manipulates the Polarization of Macrophages under Hypoxia to Sensitize Immunotherapy. ACS Nano, 2021, 15, 14522-14534.	7.3	40
468	PI3KÎ± inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8⁺T cells and promoting fatty acid metabolism. , 2021, 9, e003093.		24
469	Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma. Journal of Clinical Investigation, 2021, 131, .	3.9	49
470	TNFR2/14-3-3Îµ signaling complex instructs macrophage plasticity in inflammation and autoimmunity. Journal of Clinical Investigation, 2021, 131, .	3.9	42
471	Role of Inflammatory Mediators, Macrophages, and Neutrophils in Glioma Maintenance and Progression: Mechanistic Understanding and Potential Therapeutic Applications. Cancers, 2021, 13, 4226.	1.7	43
472	SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. Journal of Clinical Investigation, 2021, 131, .	3.9	46
473	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-Î´ and â€“Î³. Frontiers in Immunology, 2021, 12, 718621.	2.2	16
474	Baicalein Potentiated M1 Macrophage Polarization in Cancer Through Targeting PI3KÎ³/ NF-ÎºB Signaling. Frontiers in Pharmacology, 2021, 12, 743837.	1.6	20
475	Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages. Cells, 2021, 10, 2364.	1.8	13
476	Tumor-Associated Macrophages and Their Functional Transformation in the Hypoxic Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 741305.	2.2	76

#	Article	IF	Citations
477	Follicular lymphoma and macrophages: impact of approved and novel therapies. Blood Advances, 2021, 5, 4303-4312.	2.5	5
478	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2022, 231, 107986.		30
479	HIF1Î± epigenetically repressed macrophages via CRISPR/Cas9-EZH2 system for enhanced cancer immunotherapy. Bioactive Materials, 2021, 6, 2870-2880.	8.6	16
480	Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy. Kidney Diseases (Basel, Switzerland), 2022, 8, 26-43.	1.2	16
481	MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension. Oral Oncology, 2021, 120, 105401.	0.8	4
482	Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. Cancers, 2021, 13, 4712.	1.7	29
483	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. Journal of Cellular Physiology, 2022, 237, 346-372.	2.0	13
484	Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma. Journal of Inflammation Research, 2021, Volume 14, 4969-4985.	1.6	7
485	Integrated safety analysis of umbralisib, a dual PI3KÎ´/CK1Îµ inhibitor, in relapsed/refractory lymphoid malignancies. Blood Advances, 2021, 5, 5332-5343.	2.5	13
486	Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell, 2021, 39, 1361-1374.e9.	7.7	122
487	PI3KÎ³ promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation. JHEP Reports, 2021, 3, 100359.	2.6	6
488	3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway. Life Sciences, 2021, 285, 119995.	2.0	1
489	Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. Frontiers in Oncology, 2021, 11, 738626.	1.3	9
490	Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. Cancers, 2021, 13, 4704.	1.7	9
491	The Breast Tumor Microenvironment: A Key Player in Metastatic Spread. Cancers, 2021, 13, 4798.	1.7	26
492	The mechanistic target of rapamycin complex 1 critically regulates the function of mononuclear phagocytes and promotes cardiac remodeling in acute ischemia. Journal of Molecular and Cellular Cardiology, 2021, 159, 62-79.	0.9	2
493	Guiding immunotherapy combinations: Who gets what?. Advanced Drug Delivery Reviews, 2021, 178, 113962.	6.6	8
494	PI3KÎ³Î´ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. European Journal of Cancer, 2021, 157, 450-463.	1.3	13

#	Article	IF	Citations
495	Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166263.	1.8	8
496	Exosomal Circ_0125473 Drives Macrophages Polarization Toward M2 Through miR-5787/Wnt1/Î²-Catenin Signaling Pathway in Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
497	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nature Medicine, 2021, 27, 141-151.	15.2	134
498	Cellular Indoctrination: How the Tumor Microenvironment Reeducates Macrophages Towards Nefarious Ends. , 2021, , .		0
499	Myeloid-Derived Suppressor Cell Differentiation in Cancer: Transcriptional Regulators and Enhanceosome-Mediated Mechanisms. Frontiers in Immunology, 2020, 11, 619253.	2.2	13
500	The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. Cancer Treatment and Research, 2020, 180, 173-195.	0.2	48
501	Small Molecular Immune Modulators as Anticancer Agents. Advances in Experimental Medicine and Biology, 2020, 1248, 547-618.	0.8	6
502	Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117.	0.8	22
503	The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. Clinical Genitourinary Cancer, 2018, 16, e269-e276.	0.9	39
504	Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression. EBioMedicine, 2019, 40, 118-134.	2.7	50
505	Inhibition of Phosphatidylinositol 3-Kinase Î³ by IPI-549 Attenuates Abdominal Aortic Aneurysm Formation in Mice. European Journal of Vascular and Endovascular Surgery, 2020, 60, 254-263.	0.8	7
506	Systems pharmacology unravels the synergic target space and therapeutic potential of Rhodiola rosea L. for non-small cell lung cancer. Phytomedicine, 2020, 79, 153326.	2.3	11
507	The FBW7-MCL-1 axis is key in M1 and M2 macrophage-related colon cancer cell progression: validating the immunotherapeutic value of targeting PI3KÎ³. Experimental and Molecular Medicine, 2020, 52, 815-831.	3.2	33
508	Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. Nature Communications, 2020, 11, 609.	5.8	57
509	Macrophages as regulators of tumour immunity and immunotherapy. Nature Reviews Immunology, 2019, 19, 369-382.	10.6	1,365
510	A class of highly selective inhibitors bind to an active state of PI3KÎ³. Nature Chemical Biology, 2019, 15, 348-357.	3.9	42
511	c-Rel is a myeloid checkpoint for cancer immunotherapy. Nature Cancer, 2020, 1, 507-517.	5.7	63
512	Cancer immune resistance: can theories converge?. Emerging Topics in Life Sciences, 2017, 1, 411-419.	1.1	13

#	Article	IF	Citations
513	Hepatic Stellate Cellâ€“Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis. Seminars in Liver Disease, 2020, 40, 307-320.	1.8	76
514	Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32005-32016.	3.3	89
518	Macrophage targeting in cancer. Annals of the New York Academy of Sciences, 2021, 1499, 18-41.	1.8	134
519	Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. JCI Insight, 2019, 4, .	2.3	17
520	Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer. Journal of Clinical Investigation, 2019, 129, 3264-3276.	3.9	56
521	Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. Journal of Clinical Investigation, 2019, 129, 5151-5162.	3.9	180
522	Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. Journal of Clinical Investigation, 2018, 128, 5647-5662.	3.9	143
523	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Journal of Clinical Investigation, 2019, 129, 1278-1294.	3.9	102
524	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. Journal of Clinical Investigation, 2018, 128, 5505-5516.	3.9	193
525	Novel targeted therapies of T cell lymphomas. Journal of Hematology and Oncology, 2020, 13, 176.	6.9	36
526	Phosphoinositide-3-Kinase Î³ Is Not a Predominant Regulator of ATP-Dependent Directed Microglial Process Motility or Experience-Dependent Ocular Dominance Plasticity. ENeuro, 2020, 7, ENEURO.0311-20.2020.	0.9	10
527	Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. , 0, , 121-142.		31
528	Efferocytosis and prostate cancer skeletal metastasis: implications for intervention. Oncoscience, 2018, 5, 174-176.	0.9	8
529	Î±MSH inhibits adipose inflammation via reducing FoxOs transcription and blocking Akt/JNK pathway in mice. Oncotarget, 2017, 8, 47642-47654.	0.8	20
530	Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3KÎ±, in comparison to established pan PI3K inhibitors. Oncotarget, 2017, 8, 47725-47740.	0.8	11
531	Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness. Oncotarget, 2017, 8, 80545-80559.	0.8	33
532	The role of PI3KÎ³ in metabolism and macrophage activation. Oncotarget, 2017, 8, 106145-106146.	0.8	11
533	Promises and pitfalls of targeted agents in chronic lymphocytic leukemia. , 2020, 3, 415-444.		5

#	Article	IF	Citations
534	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3
535	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18
536	Isoform-Selective PI3K Inhibitors for Various Diseases. Current Topics in Medicinal Chemistry, 2020, 20, 1074-1092.	1.0	20
537	Double-crosser of the Immune System: Macrophages in Tumor Progression and Metastasis. Current Immunology Reviews, 2019, 15, 172-184.	1.2	51
538	The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110Î³ catalytic subunit of PI3KÎ³. Acta Pharmaceutica, 2019, 69, 111-119.	0.9	23
539	Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 351.	1.8	45
541	Trained Immunity for Personalized Cancer Immunotherapy: Current Knowledge and Future Opportunities. Frontiers in Microbiology, 2019, 10, 2924.	1.5	23
542	UBASH3B Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Prostate Cancer. Frontiers in Oncology, 2019, 9, 1517.	1.3	37
543	Selective inhibition of HDAC6 sensitizes cutaneous Tâ€‘cell lymphoma to PI3K inhibitors. Oncology Letters, 2020, 20, 533-540.	0.8	6
544	Representing Tumor-Associated Macrophages as the Angiogenesis and Tumor Microenvironment Regulator. Modern Medical Laboratory Journal, 2021, 4, 52-67.	0.2	0
545	Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genes. Bioengineered, 2021, 12, 7417-7431.	1.4	6
546	Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy. Annals of Translational Medicine, 2021, 9, 1596-1596.	0.7	9
547	Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy. Pharmaceutics, 2021, 13, 1670.	2.0	28
548	Targeting Tumor-Associated Macrophages in Cancer Immunotherapy. Cancers, 2021, 13, 5318.	1.7	26
549	Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 333-350.	4.5	22
550	Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic. Cancer Discovery, 2021, 11, 2693-2706.	7.7	89
551	Old Stars and New Players in the Brain Tumor Microenvironment. Frontiers in Cellular Neuroscience, 2021, 15, 709917.	1.8	11
552	Anti-Tumor Effects of Chinese Medicine Compounds by Regulating Immune Cells in Microenvironment. Frontiers in Oncology, 2021, 11, 746917.	1.3	7

#	Article	IF	Citations
553	Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas. International Journal of Molecular Sciences, 2021, 22, 11079.	1.8	5
554	Nanomedicines in B cell-targeting therapies. Acta Biomaterialia, 2022, 137, 1-19.	4.1	9
555	S100A9 Activates the Immunosuppressive Switch Through the PI3K/Akt Pathway to Maintain the Immune Suppression Function of Testicular Macrophages. Frontiers in Immunology, 2021, 12, 743354.	2.2	13
556	Design, Synthesis, and Structureâ€“Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase Î³ (PI3KÎ³). Journal of Medicinal Chemistry, 2022, 65, 1418-1444.	2.9	9
558	Maximizing insights from monogenic immune disorders. Current Opinion in Immunology, 2021, 73, 50-57.	2.4	2
559	Phosphoinositide 3-Kinase. , 2016, , 1-12.		0
560	Tumor-Induced Cholesterol Efflux from Macrophages Drives IL-4 Mediated Reprogramming and Tumor Progression. SSRN Electronic Journal, 0, , .	0.4	1
561	Phosphoinositide 3-Kinase. , 2018, , 3961-3972.		0
564	Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. Journal of Immunotherapy and Precision Oncology, 2019, 2, 23-35.	0.6	1
565	Myeloid cells in COVID-19 microenvironment. Signal Transduction and Targeted Therapy, 2021, 6, 372.	7.1	14
566	Reprogramming of Neutrophils as Non-canonical Antigen Presenting Cells by Radiotherapyâ€“Radiodynamic Therapy to Facilitate Immune-Mediated Tumor Regression. ACS Nano, 2021, 15, 17515-17527.	7.3	22
568	Computer Aided Screening of PI3K Inhibitor Molecules from Database. Lecture Notes in Electrical Engineering, 2020, , 746-753.	0.3	0
570	Discovery and Characterization of a Potent and Selective Inhibitor for Human Phosphoinositideâ€3â€kinase Î³. FASEB Journal, 2020, 34, 1-1.	0.2	0
571	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia, 2021, , .	3.3	14
572	Macrophages in tumor: An inflammatory perspective. Clinical Immunology, 2021, 232, 108875.	1.4	32
574	Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy. Frontiers in Medicine, 2021, 8, 713153.	1.2	1
575	Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy. Theranostics, 2022, 12, 340-361.	4.6	15
576	Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches. , 2022, 234, 108031.		17

#	Article	IF	Citations
577	Crosstalk between macrophages and natural killer cells in the tumor microenvironment. International Immunopharmacology, 2021, 101, 108374.	1.7	23
578	Towards regulatory cellular therapies in solid organ transplantation. Trends in Immunology, 2022, 43, 8-21.	2.9	6
579	Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. Cancers, 2021, 13, 5999.	1.7	6
580	Immunotherapy in Breast Cancer: When, How, and What Challenges?. Biomedicines, 2021, 9, 1687.	1.4	31
581	Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches. Frontiers in Endocrinology, 2021, 12, 785050.	1.5	10
582	Benznidazole Anti-Inflammatory Effects in Murine Cardiomyocytes and Macrophages Are Mediated by Class I PI3KÎ´. Frontiers in Immunology, 2021, 12, 782891.	2.2	5
583	Modulation of Myeloid-Derived Suppressor Cells Amplification by Tumor Microenvironment. Advances in Clinical Medicine, 2021, 11, 5039-5047.	0.0	0
584	The efficacy of PI3KÎ³ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells. Scientific Reports, 2022, 12, 347.	1.6	8
585	Two dimensional nanosheets as immunoregulator improve HIV vaccine efficacy. Chemical Science, 2021, 13, 178-187.	3.7	4
586	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomedicine and Pharmacotherapy, 2022, 146, 112516.	2.5	38
587	Perspective on the Immunotherapy of Esophageal Cancer. , 2021, , 43-56.		0
588	Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. Cancers, 2021, 13, 6175.	1.7	20
589	Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective. Cancers, 2022, 14, 510.	1.7	7
590	Innate Immunity and Cancer Pathophysiology. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 425-457.	9.6	41
591	The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype. Cell Death and Disease, 2022, 13, 36.	2.7	8
592	Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3KÎ±/Î²/Î´ treatment. Nature Communications, 2022, 13, 182.	5.8	40
593	PI3KÎ³ Signal Regulates Macrophage Recruitment to Injured Tissue for Regenerative Cell Survival. SSRN Electronic Journal, 0, , .	0.4	0
594	Targeting PI3KÎ³/AKT Pathway Remodels LC3â€Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation. Advanced Science, 2022, 9, e2102182.	5.6	14

#	Article	IF	Citations
595	Repolarization of Unbalanced Macrophages: Unmet Medical Need in Chronic Inflammation and Cancer. International Journal of Molecular Sciences, 2022, 23, 1496.	1.8	16
596	Advances in Antitumor Strategies Targeting Tumor-Associated Macrophages. World Journal of Cancer Research, 2022, 12, 23-32.	0.1	1
597	Self-assembled tetrahedral framework nucleic acid mediates tumor-associated macrophage reprogramming and restores antitumor immunity. Molecular Therapy - Nucleic Acids, 2022, 27, 763-773.	2.3	7
598	Immunostimulation of tumor microenvironment by targeting tumor-associated macrophages with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy. Journal of Controlled Release, 2022, 343, 78-88.	4.8	6
599	Leveraging macrophages for cancer theranostics. Advanced Drug Delivery Reviews, 2022, 183, 114136.	6.6	21
600	The Regulation of Microglial Cell Polarization in the Tumor Microenvironment: A New Potential Strategy for Auxiliary Treatment of Gliomaâ€”A Review. Cellular and Molecular Neurobiology, 2023, 43, 193-204.	1.7	1
601	Phosphoinositide-Binding Protein TIPE1 Promotes Alternative Activation of Macrophages and Tumor Progression via PIP3/Akt/TGFÎ² Axis. Cancer Research, 2022, 82, 1603-1616.	0.4	17
602	Inactivation of EGLN3 hydroxylase facilitates Erk3 degradation via autophagy and impedes lung cancer growth. Oncogene, 2022, 41, 1752-1766.	2.6	22
603	Strategies targeting tumor immune and stromal microenvironment and their clinical relevance. Advanced Drug Delivery Reviews, 2022, 183, 114137.	6.6	28
604	Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Experimental Hematology and Oncology, 2021, 10, 60.	2.0	53
605	Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy. Frontiers in Medicine, 2021, 8, 713153.	1.2	13
606	Role of macrophages in tumor development. , 2022, , 113-164.		0
607	Metabolism in tumor-associated macrophages. International Review of Cell and Molecular Biology, 2022, 367, 65-100.	1.6	10
609	Macrophages and Metabolic Reprograming in the Tumor Microenvironment. Frontiers in Oncology, 2022, 12, 795159.	1.3	11
610	Engineering ROSâ€Responsive Bioscaffolds for Disrupting Myeloid Cellâ€Driven Immunosuppressive Niche to Enhance PDâ€L1 Blockadeâ€Based Postablative Immunotherapy. Advanced Science, 2022, 9, e2104619.	5.6	14
611	Analysis of Gene Co-Expression Network to Identify the Role of CD8 + T Cell Infiltration-Related Biomarkers in High-Grade Glioma. International Journal of General Medicine, 2022, Volume 15, 1879-1890.	0.8	4
612	Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3KÎ³ inhibitor can enhance immunogenicity and eradicate tumors. , 2022, 10, e003564.		6
613	The Unfolded Protein Response at the Tumor-Immune Interface. Frontiers in Immunology, 2022, 13, 823157.	2.2	11

#	Article	IF	Citations
614	Fatty acids secreted from head and neck cancer induce M2-like Macrophages. Journal of Leukocyte Biology, 2022, 112, 617-628.	1.5	4
615	Harnessing antiâ€tumor and tumorâ€tropism functions of macrophages via nanotechnology for tumor immunotherapy. Exploration, 2022, 2, .	5.4	64
616	Chloride intercellular channel 3 suppressionâ€mediated macrophage polarization: a potential indicator of poorâ€‰prognosis of hepatitis B virusâ€related acuteâ€onâ€chronic liver failure. Immunology and Cell Biology, 2022, 100, 323-337.	1.0	5
617	Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 2022, 10, 830208.	1.8	13
618	Structural Insights from Molecular Modeling of Isoindolin-1-One Derivatives as PI3KÎ³ Inhibitors against Gastric Carcinoma. Biomedicines, 2022, 10, 813.	1.4	7
619	PI3KÎ´/Î³ inhibitor BR101801 extrinsically potentiates effector CD8⁺T cell-dependent antitumor immunity and abscopal effect after local irradiation. , 2022, 10, e003762.		7
620	Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity. Cancers, 2022, 14, 1390.	1.7	8
621	Clinical relevance of tumour-associated macrophages. Nature Reviews Clinical Oncology, 2022, 19, 402-421.	12.5	250
623	PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives. Cancers, 2022, 14, 1571.	1.7	17
624	Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers. Cancers, 2022, 14, 1681.	1.7	64
625	Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials. Molecular Therapy - Oncolytics, 2022, 24, 799-813.	2.0	26
626	PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. , 2022, 10, e003402.		21
627	PI3KÎ³ stimulates a high molecular weight form of myosin light chain kinase to promote myeloid cell adhesion and tumor inflammation. Nature Communications, 2022, 13, 1768.	5.8	4
628	Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies. Current Oncology Reports, 2022, 24, 1003-1014.	1.8	5
629	Novel Immunotherapies for Osteosarcoma. Frontiers in Oncology, 2022, 12, 830546.	1.3	25
630	High miR203a-3p and miR-375 expression in the airways of smokers with and without COPD. Scientific Reports, 2022, 12, 5610.	1.6	5
631	Metabolism of tissue macrophages in homeostasis and pathology. Cellular and Molecular Immunology, 2022, 19, 384-408.	4.8	117
632	Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. Journal of Experimental Medicine, 2022, 219, .	4.2	53

#	Article	IF	Citations
633	Polarized Macrophages in Periodontitis: Characteristics, Function, and Molecular Signaling. Frontiers in Immunology, 2021, 12, 763334.	2.2	79
634	Macrophages play a role in inflammatory transformation of colorectal cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 2013-2028.	0.8	6
635	Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Molecular Medicine, 2022, 14, e14502.	3.3	23
636	Identification and Validation of the lncRNA BACE1-AS as Immune-Related Influencing Factor in Tumorigenesis following Pan-Carcinoma Analysis. Journal of Immunology Research, 2021, 2021, 1-21.	0.9	6
637	Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapyâ€"An Integrated View into Other Neoplasms and Chemokine Networks. Cells, 2022, 11, 120.	1.8	14
638	Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics. International Journal of Molecular Sciences, 2022, 23, 405.	1.8	11
639	The role of PI3KÎ³ in the immune system: new insights and translational implications. Nature Reviews Immunology, 2022, 22, 687-700.	10.6	22
641	Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cellâ€like properties and phosphoinositide 3â€kinase inhibitor insensitivity. Molecular Carcinogenesis, 2022, 61, 664-676.	1.3	3
642	Relationship Between Serum Cytokine Profile and Circulating Neutrophils Phenotype in Patients with Benign Ovarian Tumors and Ovarian Cancer. BioNanoScience, 0, , 1.	1.5	0
643	QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3KÎ³) inhibitors using MLR and ANN methods. Scientific Reports, 2022, 12, 6090.	1.6	9
666	Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. Science Advances, 2022, 8, eabj7002.	4.7	95
669	Controlling Immunoregulatory Cell Activity for Effective Photodynamic Therapy of Cancer. Methods in Molecular Biology, 2022, 2451, 569-577.	0.4	1
670	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. Cancers, 2022, 14, 2161.	1.7	15
671	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. Cancers, 2022, 14, 2177.	1.7	2
672	Albumin nanoparticle containing a PI3KÎ³ inhibitor and paclitaxel in combination with Î±-PD1 induces tumor remission of breast cancer in mice. Science Translational Medicine, 2022, 14, eabl3649.	5.8	34
673	A review of biologically active flavonoids as inducers of autophagy and apoptosis in neoplastic cells and as cytoprotective agents in nonâ€neoplastic cells. Cell Biology International, 2022, 46, 1179-1195.	1.4	14
674	Overcoming resistance to oncolytic virus M1 by targeting PI3K-Î³ in tumor associated myeloid cells. Molecular Therapy, 2022, , .	3.7	1
675	Kinases on Double Duty: A Review of UniProtKB Annotated Bifunctionality within the Kinome. Biomolecules, 2022, 12, 685.	1.8	0

#	Article	IF	Citations
676	Downregulation of miR-122-5p Activates Glycolysis via PKM2 in Kupffer Cells of Rat and Mouse Models of Non-Alcoholic Steatohepatitis. International Journal of Molecular Sciences, 2022, 23, 5230.	1.8	11
677	An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy. Cells, 2022, 11, 1583.	1.8	10
678	The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma. Frontiers in Oncology, 2022, 12, .	1.3	1
679	Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils. Frontiers in Oncology, 2022, 12, .	1.3	11
680	Crosstalk between ILâ€15RÎ±⁺tumorâ€associated macrophages and breast cancer cells reduces CD8⁺T cell recruitment. Cancer Communications, 2022, 42, 536-557.	3.7	15
681	DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma. Frontiers in Immunology, 2022, 13, .	2.2	6
682	Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends in Immunology, 2022, 43, 523-545.	2.9	176
683	Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis. Nature Communications, 2022, 13, .	5.8	60
684	Turning adversity into opportunity: Small extracellular vesicles as nanocarriers for tumorâ€associated macrophages reâ€education. Bioengineering and Translational Medicine, 2023, 8, .	3.9	3
686	Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells. Biomolecules, 2022, 12, 850.	1.8	17
687	Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. Biomedicines, 2022, 10, 1493.	1.4	14
688	Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy. Science Advances, 2022, 8, .	4.7	16
689	Myeloid cell-targeted therapies for solid tumours. Nature Reviews Immunology, 2023, 23, 106-120.	10.6	74
690	Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy?. European Journal of Pharmacology, 2022, 928, 175087.	1.7	13
691	Polysaccharides of Brassica rapa L. attenuate tumor growth via shifting macrophages to <scp>M1</scp>â€like phenotype. Phytotherapy Research, 2022, 36, 3957-3968.	2.8	4
692	3,3â€²-Diindolylmethane improves antitumor immune responses of PD-1 blockade via inhibiting myeloid-derived suppressor cells. Chinese Medicine, 2022, 17, .	1.6	2
693	The NOTCH4-GATA4-IRG1 axis as a novel target in early-onset colorectal cancer. Cytokine and Growth Factor Reviews, 2022, 67, 25-34.	3.2	10
694	Discovery, Optimization, and Evaluation of Potent and Selective PI3KÎ´Î³ Dual Inhibitors for the Treatment of B-cell Malignancies. Journal of Medicinal Chemistry, 2022, 65, 9893-9917.	2.9	2

#	Article	IF	Citations
695	Cancer-Associated Fibroblast-Derived Exosomal miRNA-320a Promotes Macrophage M2 Polarization In Vitro by Regulating PTEN/PI3KÎ³ Signaling in Pancreatic Cancer. Journal of Oncology, 2022, 2022, 1-11.	0.6	10
696	Mechanical checkpoint regulates monocyte differentiation in fibrotic niches. Nature Materials, 2022, 21, 939-950.	13.3	22
697	Current status of phosphoinotiside-3 kinase inhibitors in blood cancers. Current Opinion in Oncology, 2022, 34, 540-545.	1.1	7
698	Direct TLR2 Signaling Through mTOR and TBK1 Induces C/EBPÎ² and IRF7-Dependent Macrophage Differentiation in Hematopoietic Stem and Progenitor Cells. Stem Cells, 2022, 40, 949-962.	1.4	3
699	The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
700	The complex role of tumor-infiltrating macrophages. Nature Immunology, 2022, 23, 1148-1156.	7.0	194
701	Spatially targeting and regulating tumor-associated macrophages using a raspberry-like micellar system sensitizes pancreatic cancer chemoimmunotherapy. Nanoscale, 0, , .	2.8	6
703	Exosome-guided direct reprogramming of tumor-associated macrophages from protumorigenic to antitumorigenic to fight cancer. Bioactive Materials, 2023, 25, 527-540.	8.6	11
704	A Naive Bayes model on lung adenocarcinoma projection based on tumor microenvironment and weighted gene co-expression network analysis. Infectious Disease Modelling, 2022, 7, 498-509.	1.2	1
705	Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. EBioMedicine, 2022, 83, 104239.	2.7	11
706	Boosting doxil-based chemoimmunotherapy via reprogramming tumor-associated macrophages. Chemical Engineering Journal, 2023, 451, 138971.	6.6	3
707	Current Status and Prospects of Clinical Treatment of Osteosarcoma. Technology in Cancer Research and Treatment, 2022, 21, 153303382211246.	0.8	16
708	Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer. , 2022, , .		0
710	Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy. Seminars in Immunopathology, 2023, 45, 163-186.	2.8	14
711	Development of a Robust and Scalable Synthetic Route for a Potent and Selective Isoindolinone PI3KÎ³ Inhibitor. Organic Process Research and Development, 2022, 26, 2915-2925.	1.3	3
712	Crosstalk between epithelium, myeloid and innate lymphoid cells during gut homeostasis and disease. Frontiers in Immunology, 0, 13, .	2.2	6
713	Network Pharmacology and in vitro Experimental Verification on Intervention of Quercetin, Present in Chinese Medicine Yishen Qutong Granules, on Esophageal Cancer. Chinese Journal of Integrative Medicine, 0, , .	0.7	0
714	A PI3KÎ³ signal regulates macrophage recruitment to injured tissue for regenerative cell survival. Development Growth and Differentiation, 0, , .	0.6	1

#	Article	IF	Citations
715	Tumor-derived exosomes deliver the tumor suppressor miR-3591-3p to induce M2 macrophage polarization and promote glioma progression. Oncogene, 2022, 41, 4618-4632.	2.6	26
716	Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies. International Journal of Molecular Sciences, 2022, 23, 10906.	1.8	7
717	Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. Journal of Clinical Investigation, 2022, 132, .	3.9	4
718	In-silico molecular modelling, MM/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo[4,5-c]quinolines as potential anti-tumor agents. Frontiers in Chemistry, 0, 10, .	1.8	27
719	DKK1 Promotes Tumor Immune Evasion and Impedes Antiâ€“PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. Cancer Immunology Research, 2022, 10, 1506-1524.	1.6	21
720	Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. Journal of Cancer, 2022, 13, 3434-3443.	1.2	16
721	PI3K Isoform Immunotherapy for Solid Tumours. Current Topics in Microbiology and Immunology, 2022, , 369-392.	0.7	1
722	Class I PI3K Biology. Current Topics in Microbiology and Immunology, 2022, , 3-49.	0.7	0
723	Major pathways involved in macrophage polarization in cancer. Frontiers in Immunology, 0, 13, .	2.2	47
724	Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. Advanced Science, 2022, 9, .	5.6	20
726	Metabolic guidance and stress in tumors modulate antigen-presenting cells. Oncogenesis, 2022, 11, .	2.1	3
727	Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies. Frontiers in Nutrition, 0, 9, .	1.6	4
728	Prostaglandin EP3 receptor activation is antinociceptive in sensory neurons via PI3KÎ³, AMPK and GRK2. British Journal of Pharmacology, 2023, 180, 441-458.	2.7	1
729	Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer. Frontiers in Immunology, 0, 13, .	2.2	11
730	Nanomodulators targeting tumor-resident immunosuppressive cells: Mechanisms and recent updates. Nano Today, 2022, 47, 101641.	6.2	7
731	Dual PI3KÎ³ inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282. Biochemical and Biophysical Research Communications, 2022, 637, 267-275.	1.0	0
732	The mechanisms on evasion of anti-tumor immune responses in gastric cancer. Frontiers in Oncology, 0, 12, .	1.3	3
733	PI3K signalling at the intersection of cardio-oncology networks: cardiac safety in the era of AI. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	0

#	Article	IF	Citations
734	Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. Communications Biology, 2022, 5, .	2.0	7
735	Beyond PI3Ks: targeting phosphoinositide kinases in disease. Nature Reviews Drug Discovery, 2023, 22, 357-386.	21.5	27
736	GSK3Î² Inhibition Prevents Macrophage Reprogramming by High-Dose Methotrexate. Journal of Innate Immunity, 2023, 15, 283-296.	1.8	1
737	Metabolic reprogramming in the immunosuppression of tumor-associated macrophages. Chinese Medical Journal, 2022, 135, 2405-2416.	0.9	9
738	Immune mechanism of low bone mineral density caused by ankylosing spondylitis based on bioinformatics and machine learning. Frontiers in Genetics, 0, 13, .	1.1	2
739	New Approaches Targeting Immuno-oncology and Tumor Microenvironment. , 2023, , 63-90.		0
740	Mechanism and adjustability of negative differential resistance of 2-phenylpyridine molecular devices by graphene electrode bending. Wuli Xuebao/Acta Physica Sinica, 2023, .	0.2	0
741	Targeting lactate metabolism for cancer immunotherapy - a matter of precision. Seminars in Cancer Biology, 2023, 88, 32-45.	4.3	12
742	Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics. Seminars in Cancer Biology, 2023, 88, 46-66.	4.3	23
743	A distinct M2 macrophage infiltrate and transcriptomic profile decisively influence adipocyte differentiation in lipedema. Frontiers in Immunology, 0, 13, .	2.2	4
744	Associating Immunotherapy and Targeted Therapies: Facts and Hopes. Clinical Cancer Research, 2023, 29, 1183-1193.	3.2	3
745	Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234.	21.5	69
746	Chemokine-like receptor 1 deficiency impedes macrophage phenotypic transformation and cardiac repair after myocardial infarction. International Journal of Cardiology, 2023, 372, 6-14.	0.8	1
747	Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade. , 2022, 10, e005447.		2
748	Inflammatory Periodontal Ligament Stem Cells Drive M1 Macrophage Polarization via Exosomal miR-143-3p-Mediated Regulation of PI3K/AKT/NF-ÎºB Signaling. Stem Cells, 2023, 41, 184-199.	1.4	13
749	Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma. BMC Medical Genomics, 2022, 15, .	0.7	1
750	Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas. Cancer Research Communications, 2022, 2, 1727-1737.	0.7	2
751	Multiâ€omicsâ€based analysis of high grade serous ovarian cancer subtypes reveals distinct molecular processes linked to patient prognosis. FEBS Open Bio, 2023, 13, 617-637.	1.0	1

#	Article	IF	Citations
752	Safety and efficacy of dual PI3K-Î´, Î³ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials. Frontiers in Immunology, 0, 13, .	2.2	6
753	Interaction of tumorâ€associated macrophages with stromal and immune components in solid tumors: Research progress (Review). International Journal of Oncology, 2023, 62, .	1.4	7
754	Leveraging molecular structure and bioactivity with chemical language models for de novo drug design. Nature Communications, 2023, 14, .	5.8	33
755	Cbl-b inhibited CD4+ T cell activation by regulating the expression of miR-99a/miR-125b. International Immunopharmacology, 2023, 115, 109677.	1.7	1
756	Nanocarriers for Active Ingredients of Chinese Medicine (AIFCM) Used in Gastrointestinal Cancer Therapy. Journal of Biomedical Nanotechnology, 2022, 18, 2279-2314.	0.5	1
757	Innate Immune Program in Formation of Tumor-Initiating Cells from Cells-of-Origin of Breast, Prostate, and Ovarian Cancers. Cancers, 2023, 15, 757.	1.7	1
758	Dendrimer-Mediated Intracellular Delivery of Fibronectin Guides Macrophage Polarization to Alleviate Acute Lung Injury. Biomacromolecules, 2023, 24, 886-895.	2.6	5
759	Application of single-cell transcriptome sequencing in gastric cancer. World Chinese Journal of Digestology, 2023, 31, 48-55.	0.0	0
760	Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions. , 2023, 244, 108370.		2
762	Trabectedin modulates macrophage polarization in the tumor-microenvironment. Role of KV1.3 and KV1.5 channels. Biomedicine and Pharmacotherapy, 2023, 161, 114548.	2.5	1
763	Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies. Drug Discovery Today, 2023, 28, 103525.	3.2	1
764	Metabolism in type 2 immune responses. Immunity, 2023, 56, 723-741.	6.6	7
765	In Situ Reprogramming of Tumorâ€Associated Macrophages with Internally and Externally Engineered Exosomes. Angewandte Chemie, 2023, 135, .	1.6	1
766	In Situ Reprogramming of Tumorâ€Associated Macrophages with Internally and Externally Engineered Exosomes. Angewandte Chemie - International Edition, 2023, 62, .	7.2	10
767	Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3KÎ´ inhibitors. Blood Cancer Journal, 2023, 13, .	2.8	0
768	Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma. International Journal of Molecular Sciences, 2023, 24, 2858.	1.8	9
769	Tumorâ€associated macrophage polarization in the inflammatory tumor microenvironment. Frontiers in Oncology, 0, 13, .	1.3	14
770	Therapeutic targeting of tumour myeloid cells. Nature Reviews Cancer, 2023, 23, 216-237.	12.8	49

#	Article	IF	Citations
771	SOHO State of the Art Updates and Next Questions | Infections in Chronic Lymphocytic Leukemia Patients: Risks and Management. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 322-332.	0.2	3
772	A timeline of tumour-associated macrophage biology. Nature Reviews Cancer, 2023, 23, 238-257.	12.8	83
773	Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia. HemaSphere, 2023, 7, e840.	1.2	1
774	Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma. , 2023, 11, e005968.		17
775	Molecular basis for differential activation of p101 and p84 complexes of PI3KÎ³ by Ras and GPCRs. Cell Reports, 2023, 42, 112172.	2.9	7
776	Mechanisms Underlying Tumor-Associated Macrophages (TAMs)-Facilitated Metastasis. , 2023, , 1-54.		0
777	Raddeanin A Enhances Mitochondrial DNAâ€cGAS/STING Axisâ€Mediated Antitumor Immunity by Targeting Transactive Responsive DNAâ€Binding Protein 43. Advanced Science, 2023, 10, .	5.6	8
778	Roles of PI3KÎ³ and PI3KÎ´ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3KÎ³/Î´ inhibitor duvelisib. Scientific Reports, 2023, 13, .	1.6	1
779	Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment. Frontiers in Immunology, 0, 14, .	2.2	6
780	HIF-1Î±-Overexpressing Mesenchymal Stem Cells Attenuate Colitis by Regulating M1-like Macrophages Polarization toward M2-like Macrophages. Biomedicines, 2023, 11, 825.	1.4	1
781	Programmed Death-Ligand 1-Positive Squamous Cell Carcinoma Spontaneously Regressed after Percutaneous Needle Biopsy. Medicina (Lithuania), 2023, 59, 631.	0.8	0
782	Towards a consensus definition of immune exclusion in cancer. Frontiers in Immunology, 0, 14, .	2.2	6
783	Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers, 2023, 15, 1987.	1.7	18
784	PDK1 inhibition reduces autophagy and cell senescence through the PI3K/AKT signalling pathway in a cigarette smoke mouse emphysema model. Experimental and Therapeutic Medicine, 2023, 25, .	0.8	0
785	Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3KÎ³ antagonist. Bioorganic and Medicinal Chemistry, 2023, 84, 117261.	1.4	0
786	Eganelisib, a First-in-Class PI3KÎ³ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clinical Cancer Research, 2023, 29, 2210-2219.	3.2	6
787	The role of macrophages in the tumor microenvironment and tumor metabolism. Seminars in Immunopathology, 2023, 45, 187-201.	2.8	7
788	Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sÃ©zary syndrome. Investigational New Drugs, 2023, 41, 350-355.	1.2	2

#	Article	IF	Citations
789	Role of Î²-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma. Cancers, 2023, 15, 2311.	1.7	6
790	Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model. Clinical Cancer Research, 2023, 29, 1984-1995.	3.2	1
791	Glucose metabolism of TAMs in tumor chemoresistance and metastasis. Trends in Cell Biology, 2023, 33, 967-978.	3.6	7
792	SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 561-574.	0.2	2
793	PI3KÎ² controls immune evasion in PTEN-deficient breast tumours. Nature, 2023, 617, 139-146.	13.7	12
794	The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy. Frontiers in Immunology, 0, 14, .	2.2	3
795	Macrophages â€“ Controlling the Bifurcation Between Tumor Existence or Regression. Advanced Biology, 2023, 7, .	1.4	0
796	G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3KÎ´ dual therapy. Frontiers in Immunology, 0, 14, .	2.2	1
797	Single-cell analyses reveal cannabidiol rewires tumor microenvironment via inhibiting alternative activation of macrophage and synergizes with anti-PD-1 in colon cancer. Journal of Pharmaceutical Analysis, 2023, 13, 726-744.	2.4	5
835	Systemic Oncosphere: Host Innate Immune System. , 2023, , 419-442.		0
844	Development of PI3KÎ³ selective inhibitors: the strategies and application. Acta Pharmacologica Sinica, 0, , .	2.8	0
877	Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. Npj Precision Oncology, 2024, 8, .	2.3	0